Literature DB >> 12033382

Bias in the Wagner-Nelson estimate of the fraction of drug absorbed.

Yibin Wang1, Jerry Nedelman.   

Abstract

PURPOSE: To examine and quantify bias in the Wagner-Nelson estimate of the fraction of drug absorbed resulting from the estimation error of the elimination rate constant (k), measurement error of the drug concentration, and the truncation error in the area under the curve.
METHODS: Bias in the Wagner-Nelson estimate was derived as a function of post-dosing time (t), k, ratio of absorption rate constant to k (r), and the coefficient of variation for estimates of k (CVk), or CV% for the observed concentration, by assuming a one-compartment model and using an independent estimate of k. The derived functions were used for evaluating the bias with r = 0.5, 3, or 6; k = 0.1 or 0.2; CV, = 0.2 or 0.4; and CV, =0.2 or 0.4; for t = 0 to 30 or 60.
RESULTS: Estimation error of k resulted in an upward bias in the Wagner-Nelson estimate that could lead to the estimate of the fraction absorbed being greater than unity. The bias resulting from the estimation error of k inflates the fraction of absorption vs. time profiles mainly in the early post-dosing period. The magnitude of the bias in the Wagner-Nelson estimate resulting from estimation error of k was mainly determined by CV,. The bias in the Wagner-Nelson estimate resulting from to estimation error in k can be dramatically reduced by use of the mean of several independent estimates of k, as in studies for development of an in vivo-in vitro correlation. The truncation error in the area under the curve can introduce a negative bias in the Wagner-Nelson estimate. This can partially offset the bias resulting from estimation error of k in the early post-dosing period. Measurement error of concentration does not introduce bias in the Wagner-Nelson estimate.
CONCLUSIONS: Estimation error of k results in an upward bias in the Wagner-Nelson estimate, mainly in the early drug absorption phase. The truncation error in AUC can result in a downward bias, which may partially offset the upward bias due to estimation error of k in the early absorption phase. Measurement error of concentration does not introduce bias. The joint effect of estimation error of k and truncation error in AUC can result in a non-monotonic fraction-of-drug-absorbed-vs-time profile. However, only estimation error of k can lead to the Wagner-Nelson estimate of fraction of drug absorbed greater than unity.

Mesh:

Year:  2002        PMID: 12033382     DOI: 10.1023/a:1015195612726

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Assessment of bioavailability of experimental controlled release microcapsules of nifedipine.

Authors:  S Mallick; B K Gupta; S K Ghosal
Journal:  Acta Pol Pharm       Date:  2000 May-Jun       Impact factor: 0.330

2.  Simple method for the estimation of absorption rate constant(ka) after oral administration.

Authors:  I Mahmood
Journal:  Am J Ther       Date:  1998-11       Impact factor: 2.688

3.  Correlation of in vitro release rate and in vivo absorption characteristics of four chlorpheniramine maleate extended-release formulations.

Authors:  P Mojaverian; E Radwanski; C C Lin; P Cho; W A Vadino; J M Rosen
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

4.  Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers.

Authors:  A A Nomeir; P Mojaverian; T Kosoglou; M B Affrime; J Nezamis; E Rodwanski; C C Lin; M N Cayen
Journal:  J Clin Pharmacol       Date:  1996-10       Impact factor: 3.126

5.  Optimization of sustained-release diltiazem formulations in man by use of an in-vitro/in-vivo correlation.

Authors:  K Yu; M Gebert; S A Altaf; D Wong; D R Friend
Journal:  J Pharm Pharmacol       Date:  1998-08       Impact factor: 3.765

6.  In-vivo/in-vitro correlation of four extended release formulations of pseudoephedrine sulfate.

Authors:  P Mojaverian; J Rosen; W A Vadino; S Liebowitz; E Radwanski
Journal:  J Pharm Biomed Anal       Date:  1997-01       Impact factor: 3.935

7.  In vitro/in vivo correlation of prolonged release dosage forms containing diltiazem HCI.

Authors:  C Caramella; F Ferrari; M C Bonferoni; M E Sangalli; M De Bernardi di Valserra; F Feletti; M R Galmozzi
Journal:  Biopharm Drug Dispos       Date:  1993-03       Impact factor: 1.627

8.  New evaluation method for in vitro/in vivo correlation of enteric-coated multiple unit dosage forms.

Authors:  T Hayashi; T Ogura; Y Takagishi
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

9.  The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets.

Authors:  M C Meyer; A B Straughn; R M Mhatre; V P Shah; R L Williams; L J Lesko
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

10.  Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism.

Authors:  Q F Xing; S Lin; Y W Chien
Journal:  J Control Release       Date:  1998-03-02       Impact factor: 9.776

View more
  2 in total

1.  Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric-coated formulations.

Authors:  Weijun Liu; Xin He; Ziqiang Li; Xiumei Gao; Yetao Ma; Mingjin Xun; Changxiao Liu
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

2.  Assessment of the gastric emptying velocity by the 13C-octanoate breath test: deconvolution versus a Wagner-Nelson analysis.

Authors:  Masaki Sanaka; Takatsugu Yamamoto; Yukako Osaki; Yasushi Kuyama
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.